Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-07 | Mr. Michael A. MarksCFO & Exec. VP | -3,34k | 0,00 | Other Disposition | - | 73,08k | -4,37% |
| 2026-02-13 | Mr. Michael R. McAleveyExec. VP and Chief Legal & Administrative Officer | -5,00k | 1,51M | Derivative Exercise and Sale | 236,61 - 540,29 | 10,99k | - |
| 2026-02-11 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | -4,00k | 2,02M | Verkauf | 505,00 | 44,38k | -8,27% |
| 2026-02-10 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | -1,03k | 519,12k | Sale to Issuer | 502,05 | 44,38k | -2,28% |
| 2026-02-10 | Ms. Erica L. RossittoSenior VP & Chief Nurse Executive | -418,00 | 209,86k | Sale to Issuer | 502,05 | 10,41k | -3,86% |
| 2026-02-10 | Mr. Michael R. McAleveyExec. VP and Chief Legal & Administrative Officer | -3,01k | 1,51M | Sale to Issuer | 502,05 | 10,99k | -21,48% |
| 2026-02-10 | Mr. Michael A. MarksCFO & Exec. VP | -1,69k | 848,46k | Sale to Issuer | 502,05 | 73,08k | -2,26% |
| 2026-02-10 | Mr. Samuel N. HazenCEO & Director | -21,32k | 10,71M | Sale to Issuer | 502,05 | 1,38M | -1,52% |
| 2026-02-10 | Mr. Jon Mack FosterExec. VP & COO | -5,89k | 2,96M | Sale to Issuer | 502,05 | 194,52k | -2,94% |
| 2026-02-10 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -3,50k | 1,76M | Sale to Issuer | 502,05 | 32,08k | -9,84% |
| 2026-02-11 | Ms. Jennifer L. BerresSenior VP & Chief HR Officer | -8,02k | 4,13M | Verkauf | 503,00 - 526,16 | 11,99k | -40,07% |
| 2026-02-10 | Ms. Jennifer L. BerresSenior VP & Chief HR Officer | -2,52k | 1,26M | Sale to Issuer | 502,05 | 11,99k | -17,34% |
| 2026-02-06 | Hercules Holding Ii, LLCUnternehmen | -36,63M | 0,00 | Other Disposition | - | 32,28M | -53,15% |
| 2026-02-06 | Frisco Holding IIUnternehmen | -36,63M | 0,00 | Other Disposition | - | - | - |
| 2026-02-05 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | 5,00k | 694,74k | Derivative Exercise and Retained Stock | 139,06 | 46,06k | 12,17% |
| 2026-02-05 | Mr. Christopher F. WyattSenior VP, Principal Accounting Officer & Controller | -5,67k | 2,13M | Derivative Exercise and Sale | 139,06 - 513,76 | 46,06k | - |
| 2026-02-05 | Mr. Jon Mack FosterExec. VP & COO | 13,25k | 1,84M | Derivative Exercise and Retained Stock | 139,06 | 184,71k | 7,73% |
| 2026-02-05 | Mr. Jon Mack FosterExec. VP & COO | -16,08k | 6,02M | Derivative Exercise and Sale | 139,06 - 513,76 | 184,71k | - |
| 2026-02-03 | Mr. Samuel N. HazenCEO & Director | -42,88k | 21,48M | Verkauf | 497,18 - 502,95 | 1,35M | -3,08% |
| 2026-02-04 | Mr. Samuel N. HazenCEO & Director | -1,05k | 520,78k | Other Disposition | 498,35 | 1,35M | -0,08% |
| 2026-02-03 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -1,50k | 747,14k | Verkauf | 498,09 | 25,95k | -5,46% |
| 2026-02-03 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -4,05k | 0,00 | Other Disposition | - | 25,95k | -13,50% |
| 2026-01-30 | Mr. Samuel N. HazenCEO & Director | 42,88k | 3,51M | Derivative Exercise and Retained Stock | 81,96 | 1,39M | 3,18% |
| 2026-01-30 | Mr. Samuel N. HazenCEO & Director | -41,48k | 16,85M | Derivative Exercise and Sale | 81,96 - 488,27 | 1,39M | - |
| 2025-11-14 | Mr. Samuel N. HazenCEO & Director | -14,83k | 0,00 | Other Disposition | - | 1,35M | -1,09% |
| 2025-11-03 | Mr. Michael R. McAleveyExec. VP and Chief Legal & Administrative Officer | -13,17k | 3,01M | Derivative Exercise and Sale | 236,61 - 473,79 | 5,62k | - |
| 2025-11-03 | Mr. Michael A. MarksCFO & Exec. VP | -330,00 | 0,00 | Other Disposition | - | 69,74k | -0,47% |
| 2025-10-31 | Mr. Samuel N. HazenCEO & Director | 29,88k | 2,08M | Derivative Exercise and Retained Stock | 69,58 | 1,36M | 2,24% |
| 2025-10-31 | Mr. Samuel N. HazenCEO & Director | -28,17k | 10,99M | Derivative Exercise and Sale | 69,58 - 459,68 | 1,36M | - |
| 2025-09-04 | Dr. Michael S. CuffeExec. VP & Chief Clinical Officer | -10,92k | 2,63M | Derivative Exercise and Sale | 173,12 - 418,84 | 31,50k | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
